 Shares of Xenetic Biosciences Inc NASDAQ: XBIO, a drug delivery platform company, were ripping higher Wednesday on markedly above-average volume. What Happened: The Framingham, Massachusetts-based company said its partner and Russian biopharma PJSC Pharmsynthez reported positive data from a pivotal Phase 3 study of Epolong that used Xenetics PolyXen to develop a treatment for anemia in patients with chronic kidney disease. 